This document summarises the Chief Medical Officer's consideration of Alexion Pharmaceuticals Australasia Pty Ltd's application to include asfotase alfa (Strensiq®) on the Life Saving Drugs Program for the treatment of peri-natal and infantile onset hypophosphatasia.
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement
About this resource
Publication date:
Publication type:
Report
Audience:
General public
Language:
English